This summary table contains detailed information about research studies. Summary tables are a useful way to look at the science behind many breast cancer guidelines and recommendations. However, to get the most out of the tables, it’s important to understand some key concepts. Learn how to read a research table.
Introduction: For women 40-49, breast cancer screening with mammography saves lives, but the benefits are less than for older women.
The U.S. Preventive Services Task Force meta-analysis of 8 randomized controlled trials found mammography modestly reduced the risk of breast cancer mortality (death) in women 40-49 .
The American College of Physicians reviewed 117 studies and found mammography reduced breast cancer mortality in women 40-49, but the risk of false positive results was high .
The U.S. Preventive Services Task Force and the American College of Physicians recommend women 40-49 make informed decisions about mammography [4-5]. This means discussing the pros and cons of mammography with their health care providers and then, together, making decisions about when to start breast cancer screening with mammography and how often to get screened.
The National Comprehensive Cancer Network recommends routine mammography for women starting at age 40 .
The American Cancer Society recommends mammography starting at age 45 and informed decision-making for women ages 40-44 .
Learn more about mammography in women 40-49.
Learn about weighing the benefits and risks of mammography.
Study selection criteria: Large randomized controlled trials and meta-analyses. Table note: Relative risk above 1 indicates increased risk. Relative risk below 1 indicates decreased risk.
Study Population(number of participants)
Age at Screening
Relative Risk of Breast Cancer Mortality (Death) in Women Who Got Screening Mammography Versus Women Who Did Not RR (95% CI)
Randomized controlled trials
Age Trial (United Kingdom) 
Canadian National Breast Cancer Screening Study 
Gothenburg Breast Screening Trial 
Kerlikowske et al. 
U.S. Preventive Services Task Force 
Cochrane Collaboration 
age less than 50
*The combined relative risk for the 3 studies with good methodology was 0.87 (0.73-1.03).
Discover the different ways you can help